Sirolimus-eluting coronary stent - Terumo

Drug Profile

Sirolimus-eluting coronary stent - Terumo

Alternative Names: Rapamycin-eluting coronary stent - Terumo; TCD-10023; Ultimaster

Latest Information Update: 13 Dec 2016

Price : $50

At a glance

  • Originator Terumo
  • Class Anti-infectives; Antifungals; Antineoplastics; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action Immunosuppressants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery disease
  • Clinical Phase Unknown Myocardial infarction

Most Recent Events

  • 06 Dec 2016 Launched for Coronary artery disease in South Korea (Intracoronary) before December 2016
  • 22 Jul 2016 Terumo Corporation and Teikyo University Hospital plan a clinical trial for Coronary artery disease in Japan (UMIN000022695)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top